Clin2
NCT07584434Likely a fitRecruiting

Safety and Dosage Study of VX-433 in Healthy People

Narcolepsy Type 1 (NT1)

Treatments studied

Part of Brain & nervous system clinical trials.

This is a first-in-human study testing a new drug called VX-433 to see how safe it is and how the body handles it. Vertex Pharmaceuticals is running this early-stage trial to understand the right dosage and side effects in healthy volunteers.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
118 people
Ages
18 years to 55 years
Study type
Interventional

Who can take part

  • Healthy adult with BMI (body weight relative to height) between 18.0 and 30.0
  • Body weight greater than 50 kg (about 110 pounds)
  • Non-smoker, or quit smoking at least 3 months ago with proof at screening
  • No fever, cold, flu, or other acute illness in the past 14 days
  • No conditions that significantly affect how your body absorbs medicines
  • If female: not pregnant, not breastfeeding, and able to avoid pregnancy for 90 days after the study ends

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07363720Recruiting· Phase 3
A study of TAK-861 for narcolepsy with cataplexy

This trial tests a new medication called TAK-861 for people with narcolepsy type 1 (NT1), which causes sudden muscle weakness (cataplexy) and extreme daytime sleepiness. The study aims to see if TAK-861 can help reduce these symptoms.

Redwood City, California
NCT07283770Recruiting· Phase 1
Safety study of VX-581 in healthy people

This trial tests the safety of a new medicine called VX-581. It is given to healthy volunteers to see how the body processes the drug and if it causes any side effects.

Overland Park, Kansas
NCT07613710Recruiting· Phase 1
Safety study of Lu AH69593 for healthy adults or narcolepsy

This study tests whether a new medication called Lu AH69593 is safe and well-tolerated in healthy adults and people with narcolepsy type 1. Researchers want to understand how the drug affects the body and whether it could help treat excessive daytime sleepiness.

Helsinki
NCT07437105Recruiting· Phase 1
Healthy volunteer study of VX-272 safety

This study tests a new investigational medicine called VX-272 in healthy volunteers. Researchers want to check its safety and how it moves through the body, so you would not have the condition the medicine is being developed for.

Tempe, Arizona
NCT07540897Recruiting· Phase 3
Testing ALKS 2680 for narcolepsy type 1

This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.

Miami, Florida
NCT07502443Recruiting· Phase 3
Study of ALKS 2680 for narcolepsy type 2

This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.

Cullman, Alabama

Hear when a new Narcolepsy Type 1 (NT1) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.